Syngenta, Jealott's Hill Research Centre, Bracknell, Berkshire RG42 6EY, UK.
Biotechnol Bioeng. 2012 Aug;109(8):1987-95. doi: 10.1002/bit.24462. Epub 2012 Feb 22.
Escherichia coli is used extensively in the production of proteins within biotechnology for a number of therapeutic applications. Here, we discuss the production and overexpression of the potential biopharmaceutical human thioredoxin protein (rhTRX) within E. coli. Overexpression of foreign molecules within the cell can put an enormous amount of stress on the translation machinery. This can lead to a misfiring in the construction of a protein resulting in populations differing slightly in amino acid composition. Whilst this may still result in a population of active molecules being expressed, it does present significant problems with molecules that are destined for clinical applications. Amino acid misincorporation of this subset could potentially result in antibodies being raised to these unnatural proteins. Cross-reaction with a patient's endogenous thioredoxin could then lead to an autoimmune phenomena and serious health implications. Generally, the issue of misincorporation appears not to be a routine regulatory concern (see ICH Q6B guidelines). Therefore, amino acid misincorporation may not have been detected, much less explored in the clinic as the occurrence or absence of these random errors is not routinely reported. Using current technologies based on proteomics, the ability to find misincorporation critically depends upon the criteria for matching theoretical and experimental mass spectrometry data. Additionally, isolation and extraction of these mistranslated proteins from the production process is both difficult and expensive. Therefore, it is advantageous to find routes for removing their production during the upstream phase. In this study, we show how modern proteomic technology can be used to identify and quantify amino acid misincorporation. Using these techniques we have shown how manipulation of gene sequence and scoping of fermentation media composition can lead to the reduction and elimination of these misincorporations in rhTRX.
大肠杆菌在生物技术中被广泛用于生产许多治疗应用的蛋白质。在这里,我们讨论了在大肠杆菌中生产和过表达潜在的生物制药人硫氧还蛋白蛋白(rhTRX)。细胞内外源分子的过表达会给翻译机制带来巨大的压力。这可能导致蛋白质的构建出现故障,导致氨基酸组成略有不同的群体。虽然这仍然可能导致表达具有活性的分子群体,但对于注定要用于临床应用的分子来说,确实存在重大问题。这种亚类的氨基酸错配可能会导致针对这些非天然蛋白质的抗体产生。与患者内源性硫氧还蛋白的交叉反应可能导致自身免疫现象和严重的健康影响。通常,错配问题似乎不是常规监管关注的问题(请参见 ICH Q6B 指南)。因此,氨基酸错配可能尚未被发现,更不用说在临床上进行探索了,因为这些随机错误的发生或不存在通常不会被报告。使用基于蛋白质组学的当前技术,发现错配的能力严重依赖于匹配理论和实验质谱数据的标准。此外,从生产过程中分离和提取这些翻译错误的蛋白质既困难又昂贵。因此,在上游阶段找到去除它们生产的途径是有利的。在这项研究中,我们展示了如何使用现代蛋白质组学技术来识别和量化氨基酸错配。使用这些技术,我们已经表明,基因序列的操纵和发酵培养基成分的范围可以导致 rhTRX 中这些错配的减少和消除。